{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T10:58:51Z","timestamp":1761821931209,"version":"build-2065373602"},"reference-count":26,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007531","name":"AES Corporation","doi-asserted-by":"publisher","award":["PI17\/01272"],"award-info":[{"award-number":["PI17\/01272"]}],"id":[{"id":"10.13039\/100007531","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002911","name":"Universidad Complutense de Madrid","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002911","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.es","revespcardiol.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revista Espa\u00f1ola de Cardiolog\u00eda (English Edition)"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1016\/j.rec.2019.09.004","type":"journal-article","created":{"date-parts":[[2019,10,17]],"date-time":"2019-10-17T17:39:55Z","timestamp":1571333995000},"page":"368-375","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Ivabradine for chronic heart rate control in persistent atrial fibrillation. Design of the BRAKE-AF project"],"prefix":"10.1016","volume":"73","author":[{"given":"Adolfo","family":"Fontenla","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda","family":"L\u00f3pez-Gil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Tamargo-Men\u00e9ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Mat\u00eda-Franc\u00e9s","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ricardo","family":"Salgado-Aranda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan Ram\u00f3n","family":"Rey-Blas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c1ngel","family":"Miracle-Blanco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Mej\u00eda-Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agust\u00edn","family":"Pastor-Fuentes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge","family":"Toquero-Ramos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel \u00c1ngel","family":"Arias","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabel","family":"Montilla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agust\u00edn","family":"G\u00f3mez de la C\u00e1mara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernando","family":"Arribas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.rec.2019.09.004_bib0135","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1093\/eurheartj\/ehi825","article-title":"Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study","volume":"27","author":"Heeringa","year":"2006","journal-title":"Eur Heart J."},{"key":"10.1016\/j.rec.2019.09.004_bib0140","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.yjmcc.2010.12.017","article-title":"Molecular architecture of the human specialised atrioventricular conduction axis","volume":"50","author":"Greener","year":"2011","journal-title":"J Mol Cell Cardiol."},{"key":"10.1016\/j.rec.2019.09.004_bib0145","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1093\/europace\/euw295","volume":"18","author":"Benussi","year":"2016","journal-title":"Europace"},{"key":"10.1016\/j.rec.2019.09.004_bib0150","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1016\/0002-9149(79)90456-9","article-title":"Inefficacy of digitalis in the control of heart rate in patients with chronic atrial fibrillation: beneficial effect of an added beta adrenergic blocking agent","volume":"44","author":"David","year":"1979","journal-title":"Am J Cardiol."},{"key":"10.1016\/j.rec.2019.09.004_bib0155","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1136\/bmj.290.6461.9","article-title":"Exercise heart rates at different serum digoxin concentrations in patients with atrial fibrillation","volume":"290","author":"Beasley","year":"1985","journal-title":"Br Med J (Clin Res Ed)."},{"key":"10.1016\/j.rec.2019.09.004_bib0160","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/S0735-1097(98)00561-0","article-title":"Ventricular rate control in chronic atrial fibrillation during daily activity and programmed exercise: a crossover open-label study of five drug regimens","volume":"33","author":"Farshi","year":"1999","journal-title":"J Am Coll Cardiol."},{"key":"10.1016\/j.rec.2019.09.004_bib0165","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.jacc.2014.03.060","article-title":"Increased mortality associated with digoxin in contemporary patients with atrial fibrillation: findings from the TREAT-AF study","volume":"64","author":"Turakhia","year":"2014","journal-title":"J Am Coll Cardiol."},{"key":"10.1016\/j.rec.2019.09.004_bib0170","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1016\/S0140-6736(14)61836-5","article-title":"Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes: a retrospective analysis of the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial","volume":"385","author":"Washam","year":"2015","journal-title":"Lancet."},{"key":"10.1016\/j.rec.2019.09.004_bib0175","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.phrs.2006.03.006","article-title":"Funny channels in the control of cardiac rhythm and mode of action of selective blockers","volume":"53","author":"DiFrancesco","year":"2006","journal-title":"Pharmacol Res."},{"key":"10.1016\/j.rec.2019.09.004_bib0180","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/S0140-6736(08)61170-8","article-title":"Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial","volume":"372","author":"Fox","year":"2008","journal-title":"Lancet."},{"key":"10.1016\/j.rec.2019.09.004_bib0185","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa1406430","article-title":"Ivabradine in stable coronary artery disease without clinical heart failure","volume":"371","author":"Fox","year":"2014","journal-title":"N Engl J Med."},{"key":"10.1016\/j.rec.2019.09.004_bib0190","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/S0140-6736(10)61198-1","article-title":"Ivabradine and outcomes in chronic heart failure (SHIFT): A randomised placebo-controlled study","volume":"376","author":"Swedberg","year":"2010","journal-title":"Lancet."},{"key":"10.1016\/j.rec.2019.09.004_bib0195","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1093\/cvr\/cvw009","article-title":"Nav1.5 N-terminal domain binding to \u03b11-syntrophin increases membrane density of human Kir2.1, Kir2.2 and Nav1.5 channels","volume":"110","author":"Matamoros","year":"2016","journal-title":"Cardiovasc Res."},{"key":"10.1016\/j.rec.2019.09.004_bib0200","doi-asserted-by":"crossref","first-page":"2346","DOI":"10.1016\/j.jacc.2010.02.028","article-title":"In humans, chronic atrial fibrillation decreases the transient outward current and ultrarapid component of the delayed rectifier current differentially on each atria and increases the slow component of the delayed rectifier current in both","volume":"55","author":"Caballero","year":"2010","journal-title":"J Am Coll Cardiol."},{"key":"10.1016\/j.rec.2019.09.004_bib0205","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1161\/CIRCEP.110.958033","article-title":"Development and validation of the Atrial Fibrillation Effect on QualiTy-of-Life (AFEQT) Questionnaire in patients with atrial fibrillation","volume":"4","author":"Spertus","year":"2011","journal-title":"Circ Arrhythm Electrophysiol."},{"key":"10.1016\/j.rec.2019.09.004_bib0210","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/00005650-199206000-00002","article-title":"The MOS 36-item Short-Form Health Survey (SF-36)","volume":"30","author":"Ware","year":"1992","journal-title":"Med Care."},{"key":"10.1016\/j.rec.2019.09.004_bib0215","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1097\/00005344-199512000-00016","article-title":"Inhibition of the subsidiary pacemaker activity by zatebradine, an If inhibitor, in the anesthetized dog heart","volume":"26","author":"Yamazaki","year":"1995","journal-title":"J Cardiovasc Pharmacol."},{"key":"10.1016\/j.rec.2019.09.004_bib0220","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1113\/jphysiol.1996.sp021424","article-title":"Electrophysiological properties of morphologically distinct cells isolated from the rabbit atrioventricular node","volume":"493","author":"Munk","year":"1996","journal-title":"J Physiol"},{"key":"10.1016\/j.rec.2019.09.004_bib0225","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1161\/01.RES.0000101913.95604.B9","article-title":"Site of origin and molecular substrate of atrioventricular junctional rhythm in the rabbit heart","volume":"93","author":"Dobrzynski","year":"2003","journal-title":"Circ Res."},{"key":"10.1016\/j.rec.2019.09.004_bib0230","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1097\/00005344-199810000-00002","article-title":"A double-blind placebo-controlled evaluation of the human electrophysiologic effects of zatebradine, a sinus node inhibitor","volume":"32","author":"Chiamvimonvat","year":"1998","journal-title":"J Cardiovasc Pharmacol."},{"key":"10.1016\/j.rec.2019.09.004_bib0235","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1016\/j.hrthm.2014.08.007","article-title":"If inhibition in the atrioventricular node by ivabradine causes rate-dependent slowing of conduction and reduces ventricular rate during atrial fibrillation","volume":"11","author":"Verrier","year":"2014","journal-title":"Heart Rhythm."},{"key":"10.1016\/j.rec.2019.09.004_bib0240","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.ijcard.2015.08.207","article-title":"Addition of ivabradine to betablockers in patients with atrial fibrillation: Effects on heart rate and exercise tolerance","volume":"202","author":"Giuseppe","year":"2016","journal-title":"Int J Cardiol."},{"key":"10.1016\/j.rec.2019.09.004_bib0245","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.ijcard.2016.09.044","article-title":"Ivabradine reduced ventricular rate in patients with non-paroxysmal atrial fibrillation","volume":"224","author":"Wongcharoen","year":"2016","journal-title":"Int J Cardiol."},{"key":"10.1016\/j.rec.2019.09.004_bib0250","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/j.recesp.2017.03.005","article-title":"Ivabradine as an alternative to AV node ablation in a patient with permanent atrial fibrillation","volume":"70","author":"Fontenla","year":"2017","journal-title":"Rev Esp Cardiol."},{"key":"10.1016\/j.rec.2019.09.004_bib0255","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.recesp.2017.05.009","article-title":"Ivabradine as AV node modulator. Promise or reality?. Response","volume":"70","author":"Fontenla","year":"2017","journal-title":"Rev Esp Cardiol."},{"key":"10.1016\/j.rec.2019.09.004_bib0260","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1111\/pace.13402","article-title":"Ivabradine is an effective antiarrhythmic therapy for congenital junctional ectopic tachycardia induced cardiomyopathy during infancy: Case studies","volume":"41","author":"Ergul","year":"2018","journal-title":"Pacing Clin Electrophysiol."}],"container-title":["Revista Espa\u00f1ola de Cardiolog\u00eda (English Edition)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1885585719302877?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1885585719302877?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T10:57:13Z","timestamp":1761821833000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1885585719302877"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":26,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["S1885585719302877"],"URL":"https:\/\/doi.org\/10.1016\/j.rec.2019.09.004","relation":{},"ISSN":["1885-5857"],"issn-type":[{"type":"print","value":"1885-5857"}],"subject":[],"published":{"date-parts":[[2020,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ivabradine for chronic heart rate control in persistent atrial fibrillation. Design of the BRAKE-AF project","name":"articletitle","label":"Article Title"},{"value":"Revista Espa\u00f1ola de Cardiolog\u00eda (English Edition)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rec.2019.09.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.recesp.2019.06.006","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Sociedad Espa\u00f1ola de Cardiolog\u00eda. Published by Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}